Washington, DC — Today the Supreme Court issued a unanimous decision in Alliance for Hippocratic Medicine v. Food and Drug Administration, ruling that the plaintiffs do not have standing to challenge the FDA’s approval of mifepristone, one of the two drugs used in the most common medication abortion regimen. While we know attacks on medication abortion will continue, this ruling ensures that access to mifepristone will remain unchanged.
“Today’s ruling in Alliance for Hippocratic Medicine v FDA means that, at least for now, access to mifepristone and the most common regimen for medication abortion will remain unchanged,” said Cat Duffy, Policy Analyst at the National Health Law Program. “More than half of all abortions in the United States are medication abortions and mifepristone has been used by millions of people to safely and effectively end their pregnancies for over twenty years. While we know attacks on medication abortion will continue, the National Health Law Program will keep fighting to protect and expand the rights and health of everyone. Abortion is health care and our work to build an equitable abortion access landscape continues.”
Today’s ruling also preserves access to medication abortion via telehealth and NHeLP will continue our longstanding work to improve and expand access to telehealth medication abortion (TMAB) for Medicaid enrollees and other underserved populations.
Members of the press who are interested in further discussing this decision with our team of Sexual and Reproductive Health experts can contact our Director of Communications Andy DiAntonio at 202.621.1023 or [email protected].
About the National Health Law Program (NHeLP): For over 50 years, NHeLP has engaged in policy and litigation advocacy to advance access to quality health care for low-income and underserved individuals, please visit www.healthlaw.org.
